These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39369843)
1. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage. Huang G; Ouyang M; Xiao K; Zhou H; Zhong Z; Long S; Li Z; Zhang Y; Li L; Xiang S; Ding X Life Sci; 2024 Nov; 357():123111. PubMed ID: 39369843 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O Jin L; Kiang KM; Cheng SY; Leung GK Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658 [TBL] [Abstract][Full Text] [Related]
3. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
4. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182 [TBL] [Abstract][Full Text] [Related]
6. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. Hu YH; Jiao BH; Wang CY; Wu JL CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245 [TBL] [Abstract][Full Text] [Related]
7. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Oldrini B; Vaquero-Siguero N; Mu Q; Kroon P; Zhang Y; Galán-Ganga M; Bao Z; Wang Z; Liu H; Sa JK; Zhao J; Kim H; Rodriguez-Perales S; Nam DH; Verhaak RGW; Rabadan R; Jiang T; Wang J; Squatrito M Nat Commun; 2020 Aug; 11(1):3883. PubMed ID: 32753598 [TBL] [Abstract][Full Text] [Related]
8. The miR-26a/AP-2α/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Huang W; Zhong Z; Luo C; Xiao Y; Li L; Zhang X; Yang L; Xiao K; Ning Y; Chen L; Liu Q; Hu X; Zhang J; Ding X; Xiang S Theranostics; 2019; 9(19):5497-5516. PubMed ID: 31534499 [TBL] [Abstract][Full Text] [Related]
9. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
10. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma. Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H J Neurosurg; 2021 Mar; 134(3):701-710. PubMed ID: 32168477 [TBL] [Abstract][Full Text] [Related]
11. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
12. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
14. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489 [TBL] [Abstract][Full Text] [Related]
15. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT. Duan C; He B; Wang Y; Liu W; Bao W; Yu L; Xin J; Gui H; Lei J; Yang Z; Liu J; Tao W; Qin J; Luo J; Dong Z Sci Rep; 2024 Aug; 14(1):20199. PubMed ID: 39215105 [TBL] [Abstract][Full Text] [Related]
16. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123 [TBL] [Abstract][Full Text] [Related]
17. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related]
19. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways. Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686 [TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Recurrence and the Role of O Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]